Etanercept, a soluble receptor antagonist to tumor necrosis factor (TNF), has been demonstrated to be effective in treating moderate to severe plaque psoriasis. It inactivates and downregulates the inflammatory and immune response induced by TNF but therefore could also reduce the host defense against malignant neoplasms.1 We report the case of a patient with preexisting undiagnosed mycosis fungoides (MF) who experienced a serious deterioration of his condition while being treated with etanercept.
Lafaille P, Bouffard D, Provost N. Exacerbation of Undiagnosed Mycosis Fungoides During Treatment With Etanercept. Arch Dermatol. 2009;145(1):94–95. doi:10.1001/archdermatol.2008.526
Dermatology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.